Related Experiment Video
Updated: Oct 11, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
[Senolytics against Covid-19?]
1ADÉS (Anthropologie bioculturelle, droit, éthique et santé) UMR CNRS 7268, Aix Marseille université, Établissement français du sang. CoReBio PACA, case 901, Parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
Abstract:
The elimination of some senescent cells by « senolytic » compounds can greatly improve the health of aged mice and in some cases reverse the effects of aging. Using a microbial exposure system that closely models coronavirus infection, it is possible to largely protect old mice from the effects of viral infection. This immediately suggests clinical application of the approach, and is the aim of ongoing phase II clinical trials in Covid-19 patients.
Insights
Senolytic compounds clear aging cells, improving health and reversing aging effects in mice. This approach also protects aged mice from viral infections, with ongoing clinical trials for COVID-19 patients.
Area of Science:
- Gerontology
- Immunology
- Virology
Background:
- Senescent cells accumulate with age, contributing to age-related diseases and frailty.
- Senolytic compounds selectively eliminate senescent cells, demonstrating therapeutic potential in preclinical models.
- A novel microbial exposure system effectively models coronavirus infection in aged mice.
Discussion:
- Eliminating senescent cells significantly enhances the healthspan of aged mice.
- This senolytic strategy confers substantial protection against severe outcomes of viral infections in aged populations.
- The findings highlight a potential therapeutic avenue for age-related diseases and infectious diseases.
Key Insights:
- Senolytic therapy can reverse some aging phenotypes and improve overall health in aged mice.
- Targeting senescent cells provides protection against viral infections, including those mimicking coronavirus.
- Preclinical success strongly supports the translation of senolytics into human clinical applications.
Outlook:
- Ongoing Phase II clinical trials are evaluating senolytics in COVID-19 patients.
- Further research will explore senolytics for preventing and treating various age-related conditions and infectious diseases.
- Senolytics represent a promising frontier in aging research and therapeutic interventions.
More Related Videos
Related Concept Videos
Antidotes
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Heart Failure Drugs: Inotropic Agents
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...

